An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2013 |
| Start Date: | August 2010 |
| End Date: | December 2013 |
| Contact: | Please reference Study ID Number: ML25492 www.roche.com/about_roche/roche_worldwide.htm |
| Email: | genentechclinicaltrials@druginfo.com |
| Phone: | 888-662-6728 (U.S. Only) |
An Observational Study of the Efficacy of RoActemra in Smoking vs Non-smoking Patients With Rheumatoid Arthritis.
This observational study will assess the efficacy and safety of RoActemra/Actemra
(Tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis. Data from
patients treated in routine clinical practice with intravenous RoActemra/Actemra will be
collected for 12 months each.
Inclusion Criteria:
- Adult patients, > 18 years of age
- Rheumatoid arthritis, defined as fulfilling at least 4 of 7 American College of
Rheumatology (ACR) criteria
- Treatment with RoActemra/Actemra
Exclusion Criteria:
- Participation in interventional clinical studies
We found this trial at
1
site
Click here to add this to my saved trials
